

# CURRICULUM VITAE

---

## Hong Ni, M.D., Ph.D.

15-3-302, ming hua li,  
jie yuan Road, Tianjin300121,  
China  
(022)6022-1725 (Home)  
nihong2000\_cn@yahoo.com.cn

Ph.D., M.D., Research Assistant  
Dept. of Gynecologic Oncology  
Tianjin Cancer Institute  
Tianjin Medical University, Tianjin, P.R.China

**Education:**      **Ph.D.**      1999-2004  
Laboratory of Gynecologic Oncology  
Tianjin Cancer Institute  
Tianjin Medical University, Tianjin, P.R.China

**M.D.**      1986-1991  
Dept. of Medicine  
Tianjin Medical University, Tianjin, P.R.China

### **Position Held:**

1999-2005:      Research Assistant  
Dept. of Gynecologic Oncology  
Tianjin Cancer Institute  
Tianjin Medical University, Tianjin, P.R.China

Investigate the effect of MDM2-p53 feedback loop on sensitivity to cisplatin in wild-type p53 expressing cell line A2780 and p53 null expressing cell line SKOV-3 by stably transfected with pCMV-MDM2 plasmid. The lack of p53 protein induction after irradiation and the high expression of mdm2 were seen by Western and Northern blot. Cytotoxicity was assessed using clonogenic survival and MTT assay. Platinum content was determined by FAAS. The DNA-Platinum binding and removal was assessed. Flow Cytometry was used to detect the different distribution of cell cycle after treatment. Trypan blue exclusion by cells demonstrated membrane integrity and Annexin V-FITC/PI-FCM method was used to distinguish between apoptotic and necrotic cell death. DNA repair of cisplatin lesions was measured by Host-cell reactivation (HCR) assay. Results: MDM2 overexpression can increase cisplatin cytotoxicity in A2780 through p53. The paper has been published in Gynecological Oncology(SCI).

Now we are constructing rAAV-antip53 and investigate its effect on sensitivity to cisplatin to ovarian cancer.

1994-1999      Research Assistant  
Division of Gynecologic Oncology  
Department of Obstetrics and Gynecology

Tianjin Medical University, Tianjin, P.R.China

I mainly took part in two programs besides helping others in their investigations.

- a. Study on the oncogene bcl-2, cerB-2, p16, c-myc, p53 expression in cervical carcinoma and the inhibitory effect of antisense oligodeoxynucleotides/RNA targeted to the bcl-2 oncogene on the growth of human cervical carcinoma Hela cell line in vitro and in vivo.
- b. Construct eukaryotic expression vector with full length human telomerase catalytic sub-unit antisense cDNA and investigate the biologic effects of this vector on human ovarian cancer cell line SKOV3.

1991-1993:      Clinical Resident  
                    Department of Obstetrics and Gynecology  
                    University Hospital of Tianjin, Tianjin, P.R.China

Participated in hundreds of obstetrical and gynecological operations including ovarian and uterus tumors.

**Awards and Honors:**

- 2004            Best Presentation Award  
                    The 7th Annual Meeting of the new development in Gynecology and Obstetrics
- 2003            Government Science and Technology Prize, Tianjin, P.R.China
- 2002            Advanced National Science and Technology Award for  
                    “The construction of antisense hTERT expressing vector and its biologic effects on SKOV3, Tianjin, P.R.China
- 2001            Best Presentation Award  
                    The 3rd China-Japan-France Friendship Gynecologic Oncology Symposium  
                    Beijing, P. R. China
- 1998            Best Presentation Award  
                    The 12th Annual Meeting of the Society of Gynecologic Oncologist
- 1996            Best Presentation Award  
                    The Eighth Annual Cancer Symposium of the Society of Gynecologic Oncology
- 1990            “Ke-Chang Wang Award” for Outstanding Undergraduate Student,  
                    Tianjin, P.R.China
- 1989            Outstanding Medical Student Award, Tianjin Medical University, Tianjin,  
                    P.R.China

**Professional Memberships:**

Member of China Anti-cancer Association  
Member of Society for Gynecology and Obstetrics  
Member of Chinese Association for the Advancement of Science

### **Scientific and Laboratory Experience:**

#### Molecular Biology:

• Gene cloning: cDNA cloning, DNA subcloning, PCR cloning, mapping, purification, genomic databases and data mining techniques

- Plasmid construction
- RNA purification, northern blots
- Calcium Phosphate- and Lipofection-based , retroviral-mediated mammalian cells

Transfection, tissue culture

• PCR ,RT-PCR , PCR-SSCP, manual and automatic DNA Sequencing , cDNA array technology, DNA microarray, in situ hybridization

- Kinase assay, Reporter assay (CAT,  $\beta$ -galactosidase and Luciferase)
- Protein-DNA interaction analysis (DNA microarrays, mobility shift DNA-binding assay, DNase I footprinting, Southern blot, protein purification and crystallization, western blot)

• FACS, ELISA, APAAP immunoenzymatic labeling, immunohistochemistry, TUNEL (TdT mediated dUTP-biotin Nick End Labeling, TUNEL) method

- dendritic cell isolation

#### Model Systems:

- Mammalian ovarian cell culture, primary and secondary
- Whole animal assays (injection, surgery, whole body perfusion / fixation)
- Transgenic mouse

#### Drug sensitivity:

- clonogenic survival and MTT assay
- Annexin V-FITC/PI-FCM method
- Host-cell reactivation (HCR) assay

#### Microscopy:

- Immunocytochemistry: fluorescent and light-based visualization of fixed cellular antigens
- Cell Biology: determination of intracellular calcium levels in living cells by laser confocal microscopy

#### Computing:

- Molecular biology software / databases: GCG, BLAST sequence similarity, Entrez, primer design
- Documentation / presentation: PowerPoint, Word, WordPerfect
- Mathematics: Excel, Sigma Plot
- Internet: molecular database, Medline, HTML

### **Publications:**

**Ni, H. (1996)** The expression of c-erbB-2, c-myc, p53 in cervical carcinoma and the clinical significance. Foreign Med Sci Obstet Gynecol Fascicle 23(5): 277-281

Mi, R.-R., **Ni, H.**, Qu, Q.-X., Chen, B.-Q. (1997) The expression of Bcl-2 in cervical carcinoma and the prognostic significance. Chin J Obstet Gynecol 32(8):492-493

**Ni, H.**, Mi, R.-R., Qu, Q.-X., Chen, B.-Q. (1998) Clinical significance of c-erbB-2 oncoprotein expression in cervical carcinoma. Chin J Clin Cancer Res 25(3):191-193

**Ni, H.**, Mi, R.-R., Qu, Q.-X., Chen, B.-Q. (1998) Expression of P16 protein in cervical carcinoma and its clinical significance. Gynecol advance 7(1): 11-14

Mi, R.-R., **Ni, H.**, Qu, Q.-X., Zheng, D.-X., Yue, T.-F., Zhao, J.-M. (2000) The inhibitory effect of bcl-2 antisense oligodeoxynucleotide/RNA on the growth of cervical carcinoma in vitro. Chin J Obstet Gynecol 35(2):105-108

**Ni, H.**, Mi, R.-R. (2000) The clinical application of blood c-erbB-2 in patients with ovarian tumor. Foreign Med Sci Obstet Gynecol Fascicle 27(4):252-253

**Ni, H.**, Mi, R.-R. (2001) Premature ovarian failure. Foreign Med Sci Obstet Gynecol Fascicle 28(2):85-87

**Ni, H.**, Mi, R.-R. (2002) Antisense oligodeoxynucleotides of human telomerase catalytic sub-unit inhibits telomerase activity and proliferation in SKOV3 and COC1. Chin J Obstet Gynecol 37(4): 198-199

**Ni, H.**, Mi, R.-R. (2003) MDM2-p53 loop and cancer therapy. Foreign Med Sci Obstet Gynecol Fascicle Accepted.

**Ni, H.**, Mi, R.-R. (2003) Effects of mdm2-p53 autoregulatory feedback loop on the sensitivity of ovarian cancer to cisplatin. Chin J Med Newsletter 2(3):219-222

**Ni, H.**, Qu, Q.-X., Mi, R.-R. (2003) New development in detection of cervical intraepithelial neoplasia. Foreign Med Sci Obstet Gynecol Fascicle 30(4):264-265.

**Ni, H.**, Mi, R.-R. (2003) Prohibition of P53 in A2780 can increase the cisplatin sensitivity. Chin J Obstet Gynecol 38(7):438-439.

Mi, R.-R., **Ni, H.**, (2003) MDM2 Sensitizes a Human Ovarian Cancer Cell Line. Gynecol. Oncol. (Engl) 90(2):238-244.

Ni, H., Mi, R.-R. (2004) Strategies for ovarian cancer. *Medical Recapitulate* 10(2) 76-78

Ni, H., Mi, R.-R. (2004) Gene therapy for ovarian cancer. *Chin J Obstet Gynecol* 48(5): 343-348

### **References**

Professor MI Ruo-Ran  
Dept. of Gynecologic Oncology  
Tianjin Cancer Institute  
Tianjin Medical University, Tianjin, P.R.China  
E-mail: rranmi@hotmail.com  
Tel: 86-022-27236173

Professor Jiao Shu-Zhu  
Division of Gynecologic Oncology  
Department of Obstetrics and Gynecology  
Tianjin Medical University, Tianjin, P.R.China  
E-mail: suzhujiao@yahoo.com.cn  
Tel: 86-022-27289142

Professor Zhou Yu-Ling  
State Key Laboratory of Experimental Hematology  
Institute of Hematology  
Chinese Academy of Medical Sciences  
E-mail: ylingz@hotmail.com  
Tel: 86-022-27621472